PubMed Health⌕ Search

Biomedical subjects

A Rydzewski

Publications and source records attributed to A Rydzewski.

At least 37 records · Page 2Linked to original sources
PubMed1989

Absence of synergism between tissue-type plasminogen activator and urokinase on plasminogen activation rate in plasma.

Effects of tissue-type plasminogen activator (t-PA), urokinase (u-PA) and their combinations on plasminogen activation rate (PAR) in plasma, in vitro were investigated. T-PA and u-PA over concentrations range of 10 U/ml to 50 U/ml induced a linear, concentration dependent increase in PAR. Combinations of t-PA and u-PA in ratios of 3/1, 1/1 and 1/3 induced additive but not synergistic effect in the activation of plasminogen. We conclude, therefore, that t-PA and u-PA do not act synergistically in the activation of plasminogen in plasma in vitro.

Chromogenic Compounds↗
PubMed1989

The role of the fibrinolytic system in acute myocardial infarction after a normal exercise test.

A 67-year-old man had an acute myocardial infarction with thrombosis in the left anterior descending artery shortly after normal exercise. We were able to measure the fibrinolytic components in this patient just prior to his developing acute myocardial infarction as well as during convalescence. In this case, marked increase in total plasminogen activator inhibitor-1 (PAI-1) antigen, mainly due to free PAI-1 antigen, was observed in basal conditions before the onset of acute myocardial infarction. On the appearance of ischaemia, plasminogen activator activity was suppressed, probably due to decreased tissue plasminogen activator antigen release and increased PAI activity, compared with that during convalescence. This suggests that some patients with coronary artery disease who have a high level of free PAI-1 antigen in basal conditions may have a strong tendency to develop acute myocardial infarction, due to further impaired fibrinolysis on the induction of ischaemia.

Acute Disease↗
PubMed1986

Concentration of three thrombin inhibitors in the nephrotic syndrome in adults.

Plasma antithrombin III (AT III), alpha 1-antitrypsin (alpha 1-AT) and alpha 1-macroglobulin (alpha 1-M) concentrations were measured in 17 cases of the nephrotic syndrome (NS) in adults. The mean plasma level of AT III was normal. The AT III concentration was correlated with albuminaemia (r = +0.718, p less than 0.005), cholesterolaemia (r = -0.651, p less than 0.005) as well as with urinary protein (r = -0.531, p less than 0.05). The alpha 1-AT concentration was decreased (p less than 0.01) and correlated with serum albumin level (r = +0.643, p less than 0.01). The alpha 1-M concentration significantly increased (p less than 0.001). A negative correlation of the alpha 1-M level with serum albumin concentration (r = -0.561, p less than 0.025) and a positive correlation with the cholesterol concentration (r = +0.819, p less than 0.001) was found. AT III and alpha 1-M were inversely correlated (r = -0.706, p less than 0.005). It is considered that in NS in adults, the increase of alpha 1-M is not compensatory for AT III, and there is no objection to the use of heparin in thrombosis prophylaxis with the exception of a few cases with very low AT III levels.

Adult↗
PubMed1986

Plasma fibronectin levels in patients with glomerular proteinuria.

Plasma fibronectin concentration was measured by means of rocket immunoelectrophoresis in 20 cases of glomerular proteinuria of various origins, and correlated with urinary protein loss, serum albumin, cholesterol and plasma alpha 1 antitrypsin and alpha 2 macroglobulin. Plasma fibronectin was significantly increased in the patient's group as compared to the controls (1.91 +/- 0.659 U/ml, 1.01 +/- 0.193 U/ml respectively, p less than 0.001) and correlated with cholesterolaemia (r = 0.662, p less than 0.001). Increased plasma fibronectin may be an additional risk factor for thrombotic tendency in NS.

Adult↗
PubMed1986

Shortening of bleeding time after intranasal administration of 1-deamino-8-D-arginine vasopressin to patients with chronic uremia.

1-deamino-8-D-arginine vasopressin (DDAVP) was administered intranasally in a dose of 2 micrograms/kg BW to 17 uremic patients (16 maintained on chronic hemodialysis and 1 treated conservatively). The bleeding time was significantly shortened 120 minutes after DDAVP administration (from 18.1 +/- 7.5 minutes to 12.3 +/- 6.4 minutes p less than 0.001). Factor VIII related antigen (VIII: Ag) did not change. Factor VIII ristocetin cofactor activity (VIII: RCof) significantly increased (from 251.2 +/- 162.0 to 336.5 +/- 167.2 p less than 0.025). Platelet count decreased significantly after DDAVP (from 174.9 +/- 43.8 X 10(9)/l to 155.6 +/- 45.9 X 10(9)/l 30 minutes p less than 0.01 and 129.8 +/- 45.2 X 10(9)/l p less than 0.005 120 minutes after DDAVP). Antithrombin III concentration, and hematocrit did not change. Our data indicate that further clinical studies of intranasal DDAVP in uremic patients during episodes of bleeding are warranted.

Administration, Intranasal↗
PubMed1985

Plasma thromboxane B2 in haemodialysed patients.

Plasma thromboxane B2 (TXB2) concentration was measured in 7 cases of terminal renal failure before and after haemodialysis. The TXB2 levels were higher in the investigated group than in the control group (p less than 0.05). Haemodialysis induced a further increase in the TXB2 concentration. Increased thromboxane production may play a part in the pathogenesis of accelerated atherosclerosis in uraemic patients treated with chronic haemodialysis.

Adult↗